FVFIGP
SYRS

Flagship Ventures Fund IV General Partner’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Flagship Ventures Fund IV General Partner’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$87.2M Buy
+480,666
New +$87.2M 14.92% 3

Other funds holding SYRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Flagship Ventures Fund IV General Partner's SYRS Position: Q2 2016 in Review

Flagship Ventures Fund IV General Partner opened a new position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2016: 480,666 shares worth $87.2M. The stake represents 14.92% of the portfolio and ranks #3 among its holdings.

12 funds tracked by Wall St. Rank hold SYRS as of Q2 2016.

  • Flagship Ventures Fund IV General Partner held 480,666 shares of Syros Pharmaceuticals, Inc. Common Stock worth $87.2M as of Q2 2016.
  • Syros Pharmaceuticals, Inc. Common Stock was a new Flagship Ventures Fund IV General Partner position in Q2 2016.
  • Syros Pharmaceuticals, Inc. Common Stock made up 14.92% of Flagship Ventures Fund IV General Partner's portfolio in Q2 2016, its #3 holding.
  • 12 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2016.

Based on Flagship Ventures Fund IV General Partner's 13F filing for Q2 2016, filed 15 Aug 2016.